Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry.

Süveg, Krisztian; Putora, Paul Martin; Berghmans, Thierry; Glatzer, Markus; Kovac, Veljko; Cihoric, Nikola (2018). Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry. Lung cancer, 124, pp. 12-18. Elsevier 10.1016/j.lungcan.2018.07.007

[img] Text
1-s2.0-S0169500218304653-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (445kB) | Request a copy

OBJECTIVES Currently there are many uncertainties in the optimal treatment of malignant pleural mesothelioma (MPM), this is reflected in discrepancies between current guidelines. Our aim was to evaluate the current status of prospective interventional clinical trials within the ClinicalTrials.gov registry in MPM in order to predict a potential impact on MPM management in the next years. MATERIAL AND METHODS The records of 263.832 clinical trials registered were searched in December 2017. Trials starting between 2005 and 2017 (n = 262) were selected for further manual review. Trials including other tumour entities or mesothelioma originating outside the pleura (n = 94) were excluded, as well as trials where the primary endpoint has already been published (n = 22). RESULTS In total, 91 clinical trials were identified and selected for further analysis. Most trials had a single arm design, were in phase I, and were non-randomized. Academic centres were recorded as primary sponsors in the majority of trials (56%), followed by industry in 21%. Most studies investigated targeted (n = 42) or cytotoxic therapies (n = 39). Ten studies investigated different genetic therapies. In 67% of the trials (n = 61) targeted and/or cytotoxic therapies were involved. Treatments involving surgery were investigated in 12 trials (13%), radiotherapy in 10 trials (11%). Only five studies (6%) were phase 3 studies and one was a phase 2/3 study. Four of these five phase 3 trials investigated targeted therapies, while one trial investigated prophylactic radiotherapy of operative tracts. CONCLUSIONS Currently running trials in MPM are mostly in early phases and dominated by systemic therapies. Very few trials evaluate loco-regional therapeutic approaches. The current controversy surrounding the use of surgery and radiotherapy within multimodal therapy strategies will not be answered by these trials in the coming years.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Putora, Paul Martin; Glatzer, Markus and Cihoric, Nikola

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0169-5002

Publisher:

Elsevier

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

24 Oct 2018 07:39

Last Modified:

23 Oct 2019 06:32

Publisher DOI:

10.1016/j.lungcan.2018.07.007

PubMed ID:

30268449

Uncontrolled Keywords:

Chemotherapy Clinical trials Clinicaltrials.gov Guidelines Immunotherapy Malignant pleural mesothelioma Radiotherapy Surgery

BORIS DOI:

10.7892/boris.120604

URI:

https://boris.unibe.ch/id/eprint/120604

Actions (login required)

Edit item Edit item
Provide Feedback